Hormone replacement therapy in peri- and postmenopause

被引:5
|
作者
Henes, M. [1 ]
Huebner, S. [1 ]
机构
[1] Univ Frauenklin Tubingen, Dept Frauengesundheit, Calwerstr 7, D-72076 Tubingen, Germany
来源
INTERNIST | 2020年 / 61卷 / 06期
关键词
Perimenopausal disorders; Postmenopausal disorders; Estrogens; Progestins; Prevention; ESTROGEN PLUS PROGESTIN; VENOUS THROMBOEMBOLISM; EQUINE ESTROGEN; WOMEN; RISK; DENSITY; FRACTURE; DISEASE;
D O I
10.1007/s00108-020-00789-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peri- and postmenopausal disorders can have a significant impact on quality of life. Hormone replacement therapy (HRT) might be necessary in order to decrease women's symptoms. The German S3 guideline "Peri- and Postmenopause-Diagnostics and Therapy" (2020) provides recommendations that include the most recent evidence as well as the Women's Health Initiative (WHI) study results from 2002 and 2004. These results led to reduced prescription patterns due to a high risk of cardiovascular diseases as well as an increased risk for breast cancer if HRT had been administered. Both ongoing analyses of subgroups and other studies extenuated the WHI data, since the increased risks were neither generalizable to the typical postmenopausal patient (regarding age and risk profile) nor to the medication being used today. This article summarizes all aspects of HRT in peri- and postmenopausal women (indications, contraindications, practical approaches, risks, prevention) and provides recommendations with respect to the most recent S3 guideline.
引用
收藏
页码:558 / 564
页数:7
相关论文
共 50 条
  • [1] Practical recommendations for hormone replacement therapy in the peri- and postmenopause
    Burger, H
    Archer, D
    Barlow, D
    Birkhäuser, M
    Calaf-Alsina, J
    Gambacciani, M
    Genazzani, A
    Hadji, P
    Iversen, OE
    Kubl, H
    Lobo, RA
    Maudelonde, T
    Castro, MN
    Notelovitz, M
    Palacios, S
    Paszkowski, T
    Peer, E
    Pines, A
    Samsioe, G
    Stevenson, J
    Skouby, S
    Sturdee, D
    de Villiers, T
    Whitehead, M
    Ylikorkala, O
    CLIMACTERIC, 2004, 7 (02) : 210 - 216
  • [2] Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause
    Birkhaeuser, M. H.
    Panay, N.
    Archer, D. F.
    Barlow, D.
    Burger, H.
    Gambacciani, M.
    Pinkerton, J. A.
    Goldstein, S.
    Sturdee, D. W.
    CLIMACTERIC, 2008, 11 (02) : 108 - 123
  • [3] Influence of hormone replacement therapy during peri- and postmenopause on the risk of cancer
    Schueler-Toprak, Susanne
    Ortmann, Olaf
    GYNAKOLOGISCHE ENDOKRINOLOGIE, 2022, 20 (03): : 178 - 185
  • [4] Hormontherapie in der Peri- und PostmenopauseHormone replacement therapy in peri- and postmenopause
    M. Henes
    S. Hübner
    Der Internist, 2020, 61 : 558 - 564
  • [5] Hormone Replacement Therapy in the Peri- and Postmenopause Updated Recommendations for Use (October 2012)
    Mueck, A. O.
    GYNAKOLOGISCHE ENDOKRINOLOGIE, 2013, 11 (01): : 58 - 61
  • [6] Einfluss einer Hormonersatztherapie in der Peri- und Postmenopause auf das KrebsrisikoInfluence of hormone replacement therapy during peri- and postmenopause on the risk of cancer
    Susanne Schüler-Toprak
    Olaf Ortmann
    Gynäkologische Endokrinologie, 2022, 20 : 178 - 185
  • [7] Hormone therapy (HT) in the peri- and postmenopause: Risk consultation
    Ortmann O.
    Lattrich C.
    Diedrich K.
    Der Gynäkologe, 2010, 43 (10): : 839 - 847
  • [8] Leitlinien zur Hormontherapie (HT) in der Peri- und PostmenopauseGuidelines on hormone replacement therapy in the perimenopause and postmenopause
    D. Noss
    O. Ortmann
    Der Gynäkologe, 2008, 41 (11):
  • [9] Hormontherapie in der Peri- und Postmenopause und MalignomrisikoHormone therapy during peri- and postmenopause and cancer risk
    D. Noss
    O. Ortmann
    Gynäkologische Endokrinologie, 2010, 8 (1) : 13 - 16
  • [10] Hormonersatztherapie in der Peri- und Postmenopause und KrebsrisikoPeri- and postmenopausal hormone replacement therapy and cancer risk
    Olaf Ortmann
    Die Gynäkologie, 2024, 57 (7) : 469 - 478